Source link : https://www.newshealth.biz/health-news/novel-car-t-for-glioblastoma-induced-dramatic-responses-in-early-trial/
A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma who were treated with CARv3-TEAM-E T cells experienced “dramatic and rapid” tumor regression within days of receiving a single intraventricular infusion, reported Marcela […]
Author : News Health
Publish date : 2024-03-13 17:39:30
Copyright for syndicated content belongs to the linked Source.
in Health